GO:2000818Ontology (GO BP)GO biological process · ~7 member genes
Q-omics provides the Negative regulation of myoblast proliferation (GO:2000818) pathway profile, scoring each patient from the combined activity of its roughly 7 member genes. Pathway activity is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 8, with the highest sampling consensus in KIRP. Additionally, pathway RNA activity shows 25,736 significant cross-omics associations, again with the highest sampling consensus in LUSC. Together, these results highlight STAD, KIRP, and LUSC as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Negative regulation of myoblast proliferation survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Negative regulation of myoblast proliferation activity shows favorable associations in SKCM, but unfavorable associations in STAD, OV, UCEC, BRCA and KIRP. In the STAD Kaplan–Meier curve the high-activity group declines faster, consistent with the unfavorable association (log-rank p = .002). STAD ranks highest by sampling consensus for Negative regulation of myoblast proliferation.
This table summarizes Negative regulation of myoblast proliferation tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 8 cancer types. The strongest signals are in BRCA for RNA.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across KIRC and lower tumor activity in KIRP, BRCA, STAD, COAD and READ. In the KIRP box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.675, t-test p = .006).
This table shows molecular features associated with Negative regulation of myoblast proliferation pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in LUSC.